Alnylam Pharmaceuticals Inc (ALNY) - Financial and Strategic SWOT Analysis Review

Date: March 28, 2017
Pages: 61
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A16EE7FD068EN
Leaflet:

Download PDF Leaflet

Alnylam Pharmaceuticals Inc (ALNY) - Financial and Strategic SWOT Analysis Review
Alnylam Pharmaceuticals Inc (ALNY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Alnylam Pharmaceuticals Inc, (Alnylam) is a biopharmaceutical company which discovers, develops and commercializes therapeutics based on Ribo Nucleic Acid interference (RNAi). The company offers a broad pipeline of investigational RNAi therapeutics in the areas of genetic medicines; cardiovascular and metabolic disease; and hepatic infectious disease. It also offers Alnylam 5x15 program for advancing genetically defined disease targets for the treatment of respiratory syncytial virus and liver cancer. Alnylam employs lipid nanoparticles for intravenous systemic delivery of sRNAi to right body organs and cells so that it could trigger the RNAi mechanism. The company works in partnership with Merck, Medtronic, Roche, Novartis, Biogen, Takeda, Cubist, GlaxoSmithKline, Ascletis, The Medicines Company, Kyowa Hakko Kirin, Monsanto, and Sanofi Genzyme for advancing its RNAi therapeutics. Alnylam is headquartered in Cambridge, Massachusetts, the US.

Alnylam Pharmaceuticals Inc Key Recent Developments

Feb 08,2017: Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Recent Period Activity
Jan 03,2017: Alnylam Announces Management Change and Key Promotion
Dec 16,2016: Alnylam Presents Initial 2017 Pipeline Goals at R&D Day with Focus on Alnylam 2020 Strategy
Nov 02,2016: Alnylam Pharmaceuticals Reports Third Quarter 2016 Financial Results and Highlights Recent Period Activity
Sep 20,2016: Alnylam to Expand Global Footprint with New European Office in Maidenhead, UK

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
SECTION 1 - ABOUT THE COMPANY

Alnylam Pharmaceuticals Inc - Key Facts
Alnylam Pharmaceuticals Inc - Key Employees
Alnylam Pharmaceuticals Inc - Key Employee Biographies
Alnylam Pharmaceuticals Inc - Major Products and Services
Alnylam Pharmaceuticals Inc - Pharmaceutical Pipeline Products Data
Alnylam Pharmaceuticals Inc, Pipeline Products by Therapy Area
Alnylam Pharmaceuticals Inc, Pipeline Products by Development Phase
Alnylam Pharmaceuticals Inc - History
Alnylam Pharmaceuticals Inc - Company Statement
Alnylam Pharmaceuticals Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture

SECTION 2 – COMPANY ANALYSIS

Alnylam Pharmaceuticals Inc - Business Description
Alnylam Pharmaceuticals Inc - Corporate Strategy
Alnylam Pharmaceuticals Inc - SWOT Analysis
SWOT Analysis - Overview
Alnylam Pharmaceuticals Inc - Strengths
Alnylam Pharmaceuticals Inc - Weaknesses
Alnylam Pharmaceuticals Inc - Opportunities
Alnylam Pharmaceuticals Inc - Threats
Alnylam Pharmaceuticals Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Alnylam Pharmaceuticals Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Feb 08, 2017: Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Recent Period Activity
Jan 03, 2017: Alnylam Announces Management Change and Key Promotion
Dec 16, 2016: Alnylam Presents Initial 2017 Pipeline Goals at R&D Day with Focus on Alnylam 2020 Strategy
Nov 02, 2016: Alnylam Pharmaceuticals Reports Third Quarter 2016 Financial Results and Highlights Recent Period Activity
Sep 20, 2016: Alnylam to Expand Global Footprint with New European Office in Maidenhead, UK
Sep 19, 2016: Alnylam Expands and Strengthens Management Team as it Plans for Commercialization
Aug 04, 2016: Alnylam Pharmaceuticals Reports Second Quarter 2016 Financial Results and Highlights Recent Period Progress
Aug 04, 2016: Jacobs wins contract for new Alnylam Biopharmaceutical manufacturing facility
Jul 12, 2016: Alnylam to Host Third Annual RNAi Roundtable Webcast Series
May 02, 2016: Alnylam Pharmaceuticals Reports First Quarter 2016 Financial Results and Highlights Recent Period Progress

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Alnylam Pharmaceuticals Inc, Key Facts
Alnylam Pharmaceuticals Inc, Key Employees
Alnylam Pharmaceuticals Inc, Key Employee Biographies
Alnylam Pharmaceuticals Inc, Major Products and Services
Alnylam Pharmaceuticals Inc, Number of Pipeline Products by Development Stage
Alnylam Pharmaceuticals Inc, History
Alnylam Pharmaceuticals Inc, Subsidiaries
Alnylam Pharmaceuticals Inc, Joint Venture
Alnylam Pharmaceuticals Inc, Key Competitors
Alnylam Pharmaceuticals Inc, Ratios based on current share price
Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc (Cont.1)
Alnylam Pharmaceuticals Inc, Interim Ratios
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Alnylam Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

Alnylam Pharmaceuticals Inc, Pipeline Products by Therapy Area
Alnylam Pharmaceuticals Inc, Pipeline Products by Development Phase
Alnylam Pharmaceuticals Inc, Performance Chart (2012 - 2016)
Alnylam Pharmaceuticals Inc, Ratio Charts
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017

COMPANIES MENTIONED

Valeant Pharmaceuticals International Inc
Sylentis SAU
Silence Therapeutics Plc
Quark Pharmaceuticals Inc
MyoKardia Inc
Marina Biotech Inc
Kyowa Hakko Kirin Pharma Inc
Dicerna Pharmaceuticals Inc
Calando Pharmaceuticals, Inc. (formerly Insert Therapeutics, Inc.)
Arrowhead Pharmaceuticals Inc
Arcturus Therapeutics Inc
Arbutus Biopharma Corp
Skip to top


Ask Your Question

Alnylam Pharmaceuticals Inc (ALNY) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: